At-a-Glance
AI-guided ceftaroline dosing: Explainable machine learning models achieved higher simulated therapeutic alignment than standard weight-based dosing in young children, though findings remain exploratory.¹
Ceftriaxone use in neonates: Ceftriaxone may be considered in carefully selected low-risk neonates when alternatives are unsuitable, with defined bilirubin thresholds and close monitoring.
AAP childhood immunization policy: The AAP released its 2026 immunization schedule, maintaining routine vaccination recommendations that diverge from recent federal guidance.²
New & Notable
In a study of 20 children aged 2 to 24 months, researchers used machine learning to estimate ceftaroline doses needed to reach a target concentration of 10 mg/L. More advanced models predicted doses more accurately than traditional regression methods.
The model with the best statistical performance did not produce the most clinically useful dosing. Tree-based models resulted in therapeutic concentrations in roughly 91–94% of patients, compared with 37.5% under observed weight-based dosing.
Weight and kidney function markers, including serum creatinine and azotemia, were the strongest drivers of dose predictions, consistent with known ceftaroline pharmacokinetics. The authors used explainable AI techniques to show how individual patient factors influenced each dose recommendation.
This remains proof of concept. The cohort was small and single-center, and model-derived doses were exploratory. Larger, prospective validation is needed before clinical application.¹
Clinical Pearl
Ceftriaxone is “relatively contraindicated” in neonates, but this restriction is not absolute. When cefotaxime is unavailable and gentamicin is inappropriate, ceftriaxone may be considered on a case-by-case basis in low-risk neonates. Appropriate candidates are infants who are on full enteral feeds, have had no calcium exposure within the past 48 hours, have preserved renal function, and do not have hemolytic disease or significant hyperbilirubinemia.
If ceftriaxone is used, indirect bilirubin should be monitored every 8 hours, with continuation only if indirect bilirubin remains ≤8 mg/dL and direct bilirubin ≤2 mg/dL. Infusions should be administered over at least 30 minutes. Patient selection, monitoring thresholds, and alternative strategies are reviewed in the video Ceftriaxone’s Contraindication in Neonates: Fact or Fiction?
Pediatric Pulse
AAP Releases 2026 Childhood and Adolescent Immunization Schedule
The American Academy of Pediatrics has released its 2026 Childhood and Adolescent Immunization Schedule, formally diverging from recent federal guidance. While updated CDC recommendations shifted several vaccines toward shared clinical decision-making, the AAP continues to recommend routine immunization against 18 preventable diseases.
For pediatric clinicians and pharmacists, this divergence affects counseling, institutional policy, and documentation practices. The AAP cites measles resurgence and sustained viral burden as justification for maintaining a universal, evidence-based schedule, reinforcing vaccination as a patient safety and public health priority.²
References
Frasca M, Gazzaniga G, Graziosi A, et al. Artificial intelligence and precision medicine: a pilot study predicting optimal ceftaroline dosage for pediatric patients. Front Artif Intell. 2026;8:1702087. doi:10.3389/frai.2025.1702087.
O’Leary ST; AAP Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedule: United States, 2026. Pediatrics. 2026. doi:10.1542/peds.2025-075754.
If you received this via forwarding and would like to subscribe, you can sign up here: Subscribe to Pediatric Pearls
— Dr. Su